Published in Ochsner J on January 01, 2015
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Surgical margins for melanoma in situ. J Am Acad Dermatol (2011) 3.29
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol (2002) 1.88
Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure. J Am Acad Dermatol (1997) 1.68
Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol (2005) 1.59
Imiquimod in the treatment of lentigo maligna. Br J Dermatol (2006) 1.17
Treatment of lentigo maligna with topical imiquimod. Br J Dermatol (2003) 1.17
Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol (2003) 1.09
Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg (2007) 1.09
A study of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica (1970) 1.04
Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol (2002) 1.00
Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol (2010) 0.99
Mohs micrographic excision of melanoma using immunostains. Dermatol Surg (2000) 0.97
Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol (2000) 0.96
Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis (2007) 0.93
Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Dermatol Surg (2012) 0.92
Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol (2002) 0.92
Geometric staged excision for the treatment of lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review. Arch Dermatol (2012) 0.91
Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg (2005) 0.91
Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg (2007) 0.90
Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma. Int J Cancer (2005) 0.88
Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol (2004) 0.88
Lentigo maligna : prognosis and treatment options. Am J Clin Dermatol (2005) 0.85
Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections. Cancer (1994) 0.85
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol (2005) 0.83
The imidazoquinolines and their place in the therapy of cutaneous disease. Expert Opin Pharmacother (2003) 0.82
Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients. Dermatol Surg (2010) 0.81
Surgical treatments for lentigo maligna: a review. Dermatol Surg (2011) 0.79
Epidermal melanocytes adjacent to melanoma and the field change effect. Histopathology (1990) 0.78
The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type. Dermatol Surg (2009) 0.78
Primary amyloidosis of the breast presenting as a solitary nodule: case report and review of the literature. Ochsner J (2014) 0.82
Palliative Resection of a Giant Mesenteric Desmoid Tumor. Ochsner J (2015) 0.75
Recurrent angiomatoid fibrous histiocytoma: a case report and review of the literature. Ochsner J (2014) 0.75
Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J (2014) 0.75
Anesthetic Considerations for Intraoperative Radiation Therapy. Ochsner J (2015) 0.75